Alto Neuroscience, Inc.

NYSE:ANRO

Biotechnology

Healthcare
$25.91 +1.84%

+$0.40 today

Market cap
$1.04B
Beta
1.25
P/E (TTM)
-9.8
EPS (TTM)
-$2.26
52W Low $2.15High $28.44

Volume 0.99M

Average 0.34M

ANRO Income Before Tax

Profit after all operating and non-operating items but before income tax.

Alto Neuroscience, Inc.NYSE: ANRO

Income Before Tax · Q1 FY2026 · quarter ended Mar 2026

Income before tax remains negative

Q1 FY2026 income before tax was -$26.24M, compared with -$15.17M a year earlier. Trailing-twelve-month income before tax was -$74.31M.

Context

  • Income before tax grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income before tax holds near -$26.24M or moves back toward the trailing-twelve-month quarterly average of -$18.58M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$26.24M-62.1% QoQ
Last fiscal yearDec 2025
-$63.24M-2.9% YoY
LTMMar 2026
-$74.31M-17.6% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-73.0%——
1 year-2.9%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(63.24M) USD
Year-over-year change
-2.9%

Income Before Tax vs competitors

How ANRO compares with its peers on the latest reported figures

  • Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -17.6% is the 5th highest of 10, against a peer median of -27.2%.
ANRO Competitors
Income Before Tax for ANRO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026-$27.37M USD+52.6%——
AMRNAmarin Corporation plcLTM Mar 2026-$34.72M USD+57.8%—16.2%
DRTSAlpha Tau Medical Ltd.LTM Mar 2026-$56.86M USD-75.7%——
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026-$58.44M USD-17.3%——
ACIUAC Immune S.A.LTM Mar 2026-CHF 66.22M CHF-27.2%—1788.8%
CLLSCellectis S.A.LTM Mar 2026-$69.45M USD-15.2%—102.0%
ANROAlto Neuroscience, Inc.LTM Mar 2026-$74.31M USD-17.6%——
SLNSilence Therapeutics plcLTM Mar 2026-$85.16M USD——9241.5%
KRROKorro Bio, Inc.LTM Mar 2026-$112.77M USD-29.2%—2935.1%
LRMRLarimar Therapeutics, Inc.LTM Mar 2026-$166.01M USD-74.3%——
DBVTDBV Technologies S.A.LTM Mar 2026-$171.4M USD-49.3%——
Peer median (excluding ANRO) —-27.2%—1788.8%

Competitors are the stored peer set for ANRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue210K0000
Cost of Revenue145K342K0502K661K
Gross Profit65K(342K)0(502K)(661K)
Gross Margin31.0%————
Research & Development8.37M23.69M30.29M47M45.62M
Selling, General & Admin3.75M5.16M7.52M21.61M20.75M
Operating Expenses12.12M28.85M37.81M68.11M65.7M
Depreciation & Amortization145K342K373K502K661K
EBITDA(9.04M)(27.37M)(34.56M)(62.3M)(60.11M)
EBITDA Margin-4305.7%————
Operating Income(12.06M)(29.19M)(37.81M)(68.61M)(66.36M)
Operating Margin-5741.0%————
Interest Income2K114K2.35M8.85M6.6M
Interest Expense001.37M(1.38M)2.47M
Other Income / Expenses2.87M1.48M1.5M7.18M3.13M
Income Before Tax(9.19M)(27.71M)(36.31M)(61.43M)(63.24M)
Pre-Tax Margin-4374.8%————
Income Tax Expense00000
Net Income(9.19M)(27.71M)(36.31M)(61.43M)(63.24M)
Net Margin-4374.8%————
EPS (Basic)(0.36)(1.08)(1.35)(2.50)(2.19)
EPS (Diluted)(0.36)(1.08)(1.35)(2.50)(2.19)
Weighted Avg Shares25.57M25.57M26.88M24.6M28.85M
Weighted Avg Shares (Diluted)25.57M25.57M26.88M24.6M28.85M

Alto Neuroscience, Inc.

NYSE:ANRO

Intrinsic Alpha fair value

Locked

Current Price

$25.91

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.